Global Ankylosing Spondylitis Market to Surpass USD 8,460.7

SEATTLE, Jan. 20, 2022 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the ankylosing spondylitis market is estimated at $4,864.3 million in 2021 and should present a CAGR of 8.2% during the forecast period (2021-2028).

Key Trends and Analysis of the Global Ankylosing Spondylitis Market:

Key market trends include regulatory agency approvals of various drugs, which is expected to drive the growth of the global ankylosing spondylitis market over the forecast period. For example, in February 2021, the US Food and Drug Administration (FDA) approved the phase 2 trial of Izokibep, indicated for patients with ankylosing spondylitis, developed by Affibody AB, a company developing innovative biopharmaceuticals bi- and new generation multi-species. and Inmagene, a leading biotechnology company focused on developing therapies for immunology-related diseases in partnership. Izokibep is a modified protein. Izokibep binds to interleukin-17A (IL-17A), a pro-inflammatory protein associated with ankylosing spondylitis (AS) with nearly 1,000 times the strength of a typical IL-17 antibody. Izokibep is designed to have high potency and a long half-life.

Request a sample copy of this report @

Main market takeaways:

The global ankylosing spondylitis market is expected to grow at a CAGR of 8.2% during the forecast period owing to the increase in research and development in ankylosing spondylitis which is expected to drive the growth of the global ankylosing spondylitis market. ankylosing spondylitis during the forecast period. For example, Secukinumab, an anti-interleukin (IL)-17A monoclonal antibody, is currently the subject of a study sponsored by Novartis Pharmaceuticals, to compare its effects with Adalimumab Biosimilar, a tumor necrosis factor. [TNF] inhibitor for the treatment of ankylosing spondylitis. The study is currently undergoing phase 3 trials starting in November 2021 and is expected to complete its study by December 2021. This is the first study designed to assess the superiority of an IL inhibitor -17A, secukinumab, on a TNF inhibitor, SDZ-ADL. It is being evaluated for reducing spinal radiographic progression in AS.

Among the drug types, NSAIDs segment is estimated to dominate the global ankylosing spondylitis market in 2021, as they are used as first-line treatment for ankylosing spondylitis. For example, in January 2021, the United States Food and Drug Administration (FDA) approved a generic version of Celebrex (celecoxib), a nonsteroidal anti-inflammatory drug (NSAID). It is an oral medication used to treat pain and inflammation caused by and other disorders.

Based on the route of administration, the oral segment is estimated to hold a dominant position in the global ankylosing spondylitis market in 2021. The factor attributed to its dominance is that NSAIDs, used as a treatment option for first line for ankylosing spondylitis, consist of oral medications.

Competitive Landscape:

Key players operating in the global ankylosing spondylitis market include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd. , UCB SA, Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA and Johnson & Johnson Services, Inc.

Buy now this research report @

Market segmentation :

  • Global Ankylosing Spondylitis Market, By Drug Type:
    • Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • Disease Modifying Antirheumatic Drugs (DMARDs)
    • TNF inhibitors
  • Global Ankylosing Spondylitis Market, By Administration:
  • Global Ankylosing Spondylitis Market, By Distribution Channel:
  • Global Ankylosing Spondylitis Market, By Region:
    • North America
    • Latin America
      • By country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By country
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Russia
        • The rest of Europe
    • Asia Pacific
      • By country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia-Pacific
    • Middle East
      • By country
        • GCC
        • Israel
        • Rest of the Middle East
    • Africa
      • By region/country
        • South Africa
        • central Africa
        • North Africa

Related Market Information Reports:

Psoriatic Arthritis Market, by drug class (nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics and others), by product type (prescription and over-the-counter), by route of administration (topical , oral, and Injectable), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) – Size, share , Prospects and Opportunities Analysis, 2021 – 2028

Rheumatoid Arthritis Diagnostic Testing Market, By type of test (serological test (erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anticyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid, other tests), monitoring of RA treatment efficacy tests (Salicylate level count, muscle enzyme tests (CPK, aldolase), creatinine test)), by end user (diagnostic labs, private labs, public labs, surgery centers Ambulatory) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) – Size, Share, Prospects and Opportunities Analysis, 2019 – 2027

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. Our head office is in India, with a sales office in the world’s financial capital in the USA and sales advisors in the UK and Japan. Our customer base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Follow us: LinkedIn | Twitter


Comments are closed.